Omic genetic technologies for herbal medicines in psychiatry

Phytotherapy Research

Volumn 26, Issue 4, 2012, Pages 522-527

  Sarris, Jerome ^a,b   Ng, Chee Hong ^a   Schweitzer, Isaac ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b SWINBURNE UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

depression; epigenetics; herbal; herbomics; omic; pharmacogenomics; polymorphisms; psychiatric disorders; psychiatry

Indexed keywords

4 AMINOBUTYRIC ACID CARRIER; 4 AMINOBUTYRIC ACID RECEPTOR; ADENOSINE RECEPTOR; APOLIPOPROTEIN E; BRAIN DERIVED NEUROTROPHIC FACTOR; CATECHOL METHYLTRANSFERASE; CHINESE DRUG; CLOMIPRAMINE; CYTOCHROME P450; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; FLUOXETINE; GLYCOPROTEIN P; HEAT SHOCK PROTEIN 70; HERBACEOUS AGENT; HYPERFORIN; HYPERICIN; HYPERICUM PERFORATUM EXTRACT; KAVA; MELATONIN RECEPTOR; NORADRENALIN TRANSPORTER; PHYTODOLOR; SEROTONIN 1 RECEPTOR; SEROTONIN 2 RECEPTOR; SEROTONIN TRANSPORTER; TRYPTOPHAN HYDROXYLASE; TRYPTOPHAN HYDROXYLASE 1; UNCLASSIFIED DRUG; UNINDEXED DRUG; XIAO YAO SAN;

ANTIDEPRESSANT ACTIVITY; ANXIETY DISORDER; ARTICLE; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHRONIC DRUG ADMINISTRATION; CLOCK GENE; COGNITIVE DEFECT; COMFREY; CROCUS SATIVUS; DEPRESSION; DNA METHYLATION; DRUG TARGETING; GENE; GENE EXPRESSION; GENETIC POLYMORPHISM; GINSENG; HERBAL MEDICINE; HIPPOCAMPUS; HISTONE MODIFICATION; HTR2A GENE; MAJOR DEPRESSION; MOOD DISORDER; NONHUMAN; PHARMACOGENOMICS; PROTEIN EXPRESSION; PROTEOMICS; PSYCHIATRY; RHODIOLA; SINGLE DRUG DOSE; SLC6A4 GENE;

ANIMALS; CLINICAL TRIALS AS TOPIC; CYTOCHROME P-450 ENZYME SYSTEM; DATABASES, FACTUAL; GENE EXPRESSION; HERBAL MEDICINE; HUMANS; MENTAL DISORDERS; PHARMACOGENETICS; PHYTOTHERAPY; POLYMORPHISM, GENETIC; PROTEOMICS; PSYCHOTROPIC DRUGS;

EID: 84859584430     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.3573     Document Type: Article

References (39)

1. Amsterdam JD, Li Y, Soeller I, Rockwell K, Mao JJ, Shults J,. 2009. A randomized, double-blind, placebo-controlled trial of oral Matricaria recutita (chamomile) extract therapy for generalized anxiety disorder. J Clin Psychopharmacol 29: 378-382.
2. Bellgrove MA, Mattingley JB,. 2008. Molecular genetics of attention. Ann NY Acad Sci 1129: 200-212.
3. Bent S, Padula A, Moore D, Patterson M, Mehling W,. 2006. Valerian for sleep: A systematic review and meta-analysis. Am J Med 119: 1005-1012.
4. Brouwers N, Sleegers K, Van Broeckhoven C,. 2008. Molecular genetics of Alzheimer's disease: an update. Ann Med 40: 562-583.
5. Cho WC,. 2007. Application of proteomics in Chinese medicine research. Am J Chin Med 35: 911-922.
6. Efferth T, Miyachi H, Bartsch H,. 2007. Pharmacogenomics of a traditional Japanese herbal medicine (Kampo) for cancer therapy. Cancer Genomics Proteomics 4: 81-91.
7. Horstmann S, Binder EB,. 2009. Pharmacogenomics of antidepressant drugs. Pharmacol Ther 124: 57-73.
8. Izzo AA,. 2004. Drug interactions with St John's Wort (Hypericum perforatum): a review of the clinical evidence. Int J Clin Pharmacol Ther 42: 139-148.
9. Jordan SA, Cunningham DG, Marles RJ,. 2010. Assessment of herbal medicinal products: challenges, and opportunities to increase the knowledge base for safety assessment. Toxicol Appl Pharmacol 243: 198-216.
10. Jungke P, Ostrow G, Li JL, et al., 2011. Profiling of hypothalamic and hippocampal gene expression in chronically stressed rats treated with St John's wort extract (STW 3-VI) and fluoxetine. Psychopharmacology (Berl) 213: 757-772.
11. Kang YJ,. 2008. Herbogenomics: from traditional Chinese medicine to novel therapeutics. Exp Biol Med (Maywood) 233: 1059-1065.
12. Kato M, Serretti A,. 2010. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry 15: 473-500.
13. Kirk H, Cefalu WT, Ribnicky D, Liu Z, Eilertsen KJ,. 2008. Botanicals as epigenetic modulators for mechanisms contributing to development of metabolic syndrome. Metabolism 57: S16-S23.
14. Lambert T, Norman T,. 2008. Ethnic difference in psychotropic drug response and pharmacokinetics. In Ethno-psychopharmacology: Advances in Current Practice, Ng C, Lin K, Singh B, Chiu E, (eds). University Press: Cambridge.
15. Le Bars PL,. 2003. Response patterns of EGb 761 in Alzheimer's disease: influence of neuropsychological profiles. Pharmacopsychiatry 36 Suppl 1: S50-S55.
16. Lee SY, Kim GT, Roh SH, et al., 2009. Proteomic analysis of the anti-cancer effect of 20S-ginsenoside Rg3 in human colon cancer cell lines. Biosci Biotechnol Biochem 73: 811-816.
17. Malhotra AK, Murphy GM, Jr, Kennedy JL,. 2004. Pharmacogenetics of psychotropic drug response. Am J Psychiatry 161: 780-796.
18. Miyasaka LS, Atallah AN, Soares BG,. 2007. Passiflora for anxiety disorder. Cochrane Database Syst Rev 1: CD004518.
19. Ng CH, Schweitzer I, Norman T, Easteal S,. 2004. The emerging role of pharmacogenetics: implications for clinical psychiatry. Aust NZ J Psychiatry 38: 483-489.
20. Panossian A, Wikman G, Sarris J,. 2010. Rosenroot (Rhodiola rosea): traditional use, chemical composition, pharmacology and clinical efficacy. Phytomedicine 17: 481-493.
21. Pennington K, Focking M, McManus CA, Pariante CM, Dunn MJ, Cotter DR,. 2009. A proteomic investigation of similarities between conventional and herbal antidepressant treatments. J Psychopharmacol 23: 520-530.
22. Preskorn SH,. 2006. Pharmacogenomics, informatics, and individual drug therapy in psychiatry: past, present and future. J Psychopharmacol 20: 85-94.
23. Rahimi R, Nikfar S, Abdollahi M,. 2009. Efficacy and tolerability of Hypericum perforatum in major depressive disorder in comparison with selective serotonin reuptake inhibitors: a meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 33: 118-127.
24. Rogers PJ, Hohoff C, Heatherley SV, et al., 2010. Association of the anxiogenic and alerting effects of caffeine with ADORA2A and ADORA1 polymorphisms and habitual level of caffeine consumption. Neuropsychopharmacology 35: 1973-1983.
25. Sarris J,. 2007. Herbal medicines in the treatment of psychiatric disorders: a systematic review. Phytother Res 21: 703-716.
26. Sarris J, Kavanagh D, Byrne G, Bone K, Adams J, Deed G,. 2009. The Kava Anxiety Depression Spectrum Study (KADSS): A randomized, placebo-controlled, cross-over trial using an aqueous extract of Piper methysticum. Psychopharmacology (Berl) 205: 399-407.
27. Sarris J, Teschke R, Stough C, Scholey A, Schweitzer I,. 2011. Re-introduction of kava (Piper methysticum) to the EU: is there a way forward? Planta Med 77: 107-110.
28. Schmidt M, Betti G, Hensel A,. 2007. Saffron in phytotherapy: pharmacology and clinical uses. Wien Med Wochenschr 157: 315-319.
29. Schosser A, Kasper S,. 2009. The role of pharmacogenetics in the treatment of depression and anxiety disorders. Int Clin Psychopharmacol 24: 277-288.
30. Serretti A, Mandelli L,. 2008. The genetics of bipolar disorder: genome 'hot regions', genes, new potential candidates and future directions. Mol Psychiatry 13: 742-771.
31. Spinella M,. 2001. The Psychopharmacology of Herbal Medicine: Plant Drugs That Alter Mind, Brain and Behavior (Paperback). MIT Press: USA.
32. Stough C, Downey LA, Lloyd J, et al., 2008. Examining the nootropic effects of a special extract of Bacopa monniera on human cognitive functioning: 90 day double-blind placebo-controlled randomized trial. Phytother Res 22: 1629-1634.
33. Ulrich-Merzenich G, Zeitler H, Jobst D, Panek D, Vetter H, Wagner H,. 2007. Application of the '-Omic-' technologies in phytomedicine. Phytomedicine 14: 70-82.
34. Waddington Lamont E, Coutu DL, Cermakian N, Boivin DB,. 2010. Circadian rhythms and clock genes in psychotic disorders. Isr J Psychiatry Relat Sci 47: 27-35.
35. Williamson EM,. 2001. Synergy and other interactions in phytomedicines. Phytomedicine 8: 401-409.
36. Wolfson P, Hoffmann D,. 2003. An investigation into the efficacy of Scutellaria lateriflora in healthy volunteers. Altern Ther Health Med 9: 74.
37. Wong ML, O'Kirwan F, Hannestad JP, Irizarry KJ, Elashoff D, Licinio J,. 2004. St John's wort and imipramine-induced gene expression profiles identify cellular functions relevant to antidepressant action and novel pharmacogenetic candidates for the phenotype of antidepressant treatment response. Mol Psychiatry 9: 237-251.
38. Zhou SF,. 2009a. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet 48: 689-723.
39. Zhou SF,. 2009b. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet 48: 761-804.